Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins fray
tirzepatide
),
Eli Lilly
's blockbuster weight-loss and diabetes drug, jumped nearly nine times since its launch in March to ₹26 crore in June, a month that also saw the launch of
Wegovy
from competitor
Novo Nordisk
. In the last one month itself, Mounjaro sale doubled from ₹13 crore in May, according to data from
PharmaTrac
. So far the total sales value of Mounjaro is ₹50 crore in India.
In volume terms, the numbers over seven times since March to 88,000 units sold in June. In the last two months, the quantity of Mounjaro sold has grown threefold from 28,000 units in April, the data showed. On the other hand, a week within its launch, Wegovy that is available in self-injectable pen-filled version, recorded a sale of ₹2.53 crore, shows the data.
Doctors said the increased awareness as well as social media conversations and publicity about both the molecules is prompting many young adults in their thirties and early forties showing interest.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
10 hours ago
- Time of India
Oprah Winfrey's weight loss journey: How she lost weight and transformed her health
Oprah Winfrey's weight loss journey has been decades in the making—marked by personal challenges, health setbacks, and ultimately, a shift in mindset. From battling public scrutiny to discovering the benefits of fitness, nutrition, and medical support, Oprah's transformation is not just about the number on the scale, but about reclaiming her health and self-worth. For over 25 years, Oprah's weight was a frequent topic in the media, often used to ridicule her. Throughout her television career, she was publicly judged for her size, which contributed to years of self-blame and emotional strain. Despite being one of the most influential women in the world, she faced the same weight stigma and diet culture pressures that affect millions. How Oprah Winfrey's knee surgery became a turning point in her weight loss journey In 2021, Oprah underwent double knee surgery—an event that sparked a profound change in how she approached health. Prior to surgery, she had experienced increasing pain that limited her ability to move. After the procedure and a period of physical therapy, she slowly regained her strength and began hiking regularly. She eventually reached the point of completing 3 to 5 miles daily, and even hiked up to 10 miles on weekends. This new level of activity not only improved her physical fitness but helped her reconnect with her body and build a sustainable movement routine. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Đây có thể là thời điểm tốt nhất để giao dịch vàng trong 5 năm qua IC Markets Tìm hiểu thêm Undo Her recovery gave her a sense of vitality she hadn't felt in years. Oprah Winfrey's weight loss success is rooted in a balanced, sustainable approach rather than quick fixes or extreme dieting. She follows a consistent routine that prioritises early dinners—typically finishing her last meal by 4:00 p.m.—and drinks up to a gallon of water each day to stay hydrated and energised. Although she stepped away from the WeightWatchers board, Oprah still uses its points system to guide her portion control and food choices. Physical activity plays a key role as well, with regular hiking, walking, and strength training forming the foundation of her fitness routine. Most importantly, Oprah incorporates emotional well-being into her journey, practising self-acceptance and letting go of the guilt tied to past weight fluctuations. Her method is a reflection of long-term health and self-care, focusing on habits she can sustain for life rather than chasing a number on the scale. Oprah Winfrey's weight loss medication journey Oprah has also used a GLP-1 receptor agonist—a type of weight-loss medication approved for managing obesity and type 2 diabetes. While she hasn't publicly named the brand, GLP-1 drugs like Ozempic and Wegovy have become popular tools for weight regulation. Importantly, Oprah stresses that the medication is just one part of her health plan. She continues to exercise, eat mindfully, and stay active. For her, medication is a helpful tool—not a magic solution—and it supports her in avoiding the 'yo-yo' effect of losing and regaining weight. Oprah Winfrey on letting go of weight stigma and reclaiming her health Over the years, Oprah internalised much of the stigma directed at her body. She was often treated differently when shopping or appearing in public while over 200 lbs. She has shared that others assumed she didn't belong in certain spaces—especially high-end fashion boutiques—and that judgment was both external and internal. But today, she embraces a new outlook: health is not a punishment or an image to be perfected. It's about feeling strong, being able to move with ease, and living with purpose. She's also become vocal about the need to eliminate weight stigma in society, urging others to show compassion rather than criticism toward bodies of all sizes. Over the years, Oprah internalised much of the stigma directed at her body. She was often treated differently when shopping or appearing in public while over 200 lbs. She has shared that others assumed she didn't belong in certain spaces—especially high-end fashion boutiques—and that judgment was both external and internal. But today, she embraces a new outlook: health is not a punishment or an image to be perfected. It's about feeling strong, being able to move with ease, and living with purpose. She's also become vocal about the need to eliminate weight stigma in society, urging others to show compassion rather than criticism toward bodies of all sizes. Oprah's mantra: No goal weight, just a goal to feel good Unlike traditional weight loss stories that revolve around reaching a target weight, Oprah hasn't set a specific number for her transformation. Instead, she's focused on how she feels: light, strong, mobile, and well. Her lifestyle changes—eating better, exercising regularly, and using medication when needed—have helped her reach a point of balance. In earlier years, she did share that she lost 26 pounds while following the WeightWatchers plan. Today, her weight is estimated to be around 160 lbs, a significant drop from her highest weight of 237 lbs. Oprah Winfrey's weight loss journey is one of resilience, reflection, and reinvention. By combining medical tools, nutrition, movement, and emotional healing, she has created a lifestyle that supports her physical and mental well-being. Her story is a reminder that weight loss is deeply personal—and that health should be defined by how you feel, not how you look Also Read: How people with diabetes can safely eat mango without increasing blood sugar
Economic Times
a day ago
- Economic Times
Cipla eyes entry into India's weight management market amid rising demand and global competition
Synopsis Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader. Agencies Representative image Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25."Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders."Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added."Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability."We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
Mint
2 days ago
- Mint
Cipla to enter into weight management segment in India, says MD Umang Vohra
Drugmaker Cipla's MD and global CEO Umang Vohra has announced that the company is planning to enter into the weight management segment in India. The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra said. In the CNS segment, the Mumbai-based company has successfully in-licensed Sanofi India's CNS product range, including Frisium, a leading brand in the anti-epileptic category, he added. He also said: "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease." Several domestic pharma companies are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. American drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in India. Denmark's Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. For fiscal year 2025, Cipla reported consolidated revenue of ₹ 27,548 crore. Its consolidated net profit increased to ₹ 5,272 crore. Umang Vohra further said the company is equally committed to addressing the global crisis of anti-microbial resistance (AMR). "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," he said. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," he added.
